Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• TP53 gene mutations are common in cancer, distinguishing tumor cells from normal cells.
• This genetic difference presents a therapeutic vulnerability that can be exploited.

Purpose of the Study:

• To investigate if activating the tumor suppressor p53 can protect normal cells from chemotherapy.
• To develop a strategy that spares healthy tissues while targeting p53-deficient tumors.

Main Methods:

• Utilized Mdm2 antagonist nutlin-3 to activate p53 and induce cell cycle arrest in cancer cell lines (U2OS, HCT116).
• Assessed cell resistance to gemcitabine using clonogenic assays after sequential treatment.
• Compared responses in p53-proficient and p53-deficient cells, including non-transformed human keratinocytes.

Main Results:

• Nutlin-3 pretreatment rendered p53-proficient cells resistant to gemcitabine.
• Cells lacking functional p53 remained sensitive to gemcitabine, irrespective of nutlin-3.
• Sequential nutlin-3 and gemcitabine treatment selectively reduced clonogenicity of p53-mutated tumor cells while sparing normal keratinocytes.
• p53 activation protected against cytosine arabinoside but not doxorubicin or cisplatin.

Conclusions:

• The cell cycle arrest function of p53 can be therapeutically leveraged.
• p53 can be converted from a tumor suppressor to a protector of normal cells during chemotherapy.
• This approach holds potential for reducing chemotherapy-induced toxicity in patients.